Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM) (MUK seven)

Trial Profile

Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM) (MUK seven)

Phase of Trial: Phase II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Pomalidomide (Primary) ; Cyclophosphamide; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms MUK Seven
  • Most Recent Events

    • 12 Dec 2017 interim results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 11 May 2016 Status changed from withdrawn prior to enrolment to recruiting.
    • 17 Oct 2015 Status changed from suspended to withdrawn prior to enrolment as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top